GALDERMA GROUP AG (GALDY) - Net Assets
Based on the latest financial reports, GALDERMA GROUP AG (GALDY) has net assets worth $8.15 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.39 Billion) and total liabilities ($5.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read GALDERMA GROUP AG total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.15 Billion |
| % of Total Assets | 60.85% |
| Annual Growth Rate | 23.18% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.24 |
GALDERMA GROUP AG - Net Assets Trend (2023–2025)
This chart illustrates how GALDERMA GROUP AG's net assets have evolved over time, based on quarterly financial data. Also explore GALDERMA GROUP AG asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for GALDERMA GROUP AG (2023–2025)
The table below shows the annual net assets of GALDERMA GROUP AG from 2023 to 2025. For live valuation and market cap data, see GALDY company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $8.15 Billion | +4.61% |
| 2024-12-31 | $7.79 Billion | +45.09% |
| 2023-12-31 | $5.37 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GALDERMA GROUP AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 724800000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $6.35 Billion | 77.88% |
| Other Components | $1.80 Billion | 22.12% |
| Total Equity | $8.15 Billion | 100.00% |
GALDERMA GROUP AG Competitors by Market Cap
The table below lists competitors of GALDERMA GROUP AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ambev SA ADR
NYSE:ABEV
|
$45.92 Billion |
|
Cardinal Health Inc
NYSE:CAH
|
$45.94 Billion |
|
Siemens Healthineers AG
F:SHL
|
$45.96 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
$45.97 Billion |
|
HOLCIM NEW(U.ADR)1/5/SF2
F:HLB
|
$45.78 Billion |
|
KBC GROEP N.V. ADR
F:KDB0
|
$45.62 Billion |
|
BASF SE
XETRA:BAS
|
$45.45 Billion |
|
Occidental Petroleum Corporation
NYSE:OXY
|
$45.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GALDERMA GROUP AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,790,000,000 to 8,150,000,000, a change of 360,000,000 (4.6%).
- Net income of 613,000,000 contributed positively to equity growth.
- Dividend payments of 41,000,000 reduced retained earnings.
- Share repurchases of 363,000,000 reduced equity.
- Other factors increased equity by 151,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $613.00 Million | +7.52% |
| Dividends Paid | $41.00 Million | -0.5% |
| Share Repurchases | $363.00 Million | -4.45% |
| Other Changes | $151.00 Million | +1.85% |
| Total Change | $- | 4.62% |
Book Value vs Market Value Analysis
This analysis compares GALDERMA GROUP AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.86x to 1.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $22.60 | $42.09 | x |
| 2024-12-31 | $32.81 | $42.09 | x |
| 2025-12-31 | $34.74 | $42.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GALDERMA GROUP AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.52%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.70%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.64x
- Recent ROE (7.52%) is above the historical average (3.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -1.06% | -1.38% | 0.33x | 2.32x | $-593.90 Million |
| 2024 | 2.97% | 5.20% | 0.35x | 1.62x | $-548.00 Million |
| 2025 | 7.52% | 11.70% | 0.39x | 1.64x | $-202.00 Million |
Industry Comparison
This section compares GALDERMA GROUP AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $459,373,250
- Average return on equity (ROE) among peers: -63.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GALDERMA GROUP AG (GALDY) | $8.15 Billion | -1.06% | 0.64x | $45.88 Billion |
| Aurora Cannabis Inc (ACB) | $605.09 Million | 0.26% | 0.40x | $197.35 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.82 Billion | 13.28% | 0.39x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $164.76 Million | -183.14% | 0.18x | $1.77 Billion |
| Amphastar P (AMPH) | $337.33 Million | 1.34% | 0.35x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.92 Million | -75.48% | 0.12x | $1.80 Billion |
About GALDERMA GROUP AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more